Medicosurgical Intensive Care Unit, Poissy Saint-Germain Hospital, Poissy, France.
Am J Respir Crit Care Med. 2010 Oct 1;182(7):910-7. doi: 10.1164/rccm.200906-0838OC. Epub 2010 Jun 3.
Ventilator-associated pneumonia (VAP) causes substantial morbidity and mortality. The influence of subglottic secretion drainage (SSD) in preventing VAP remains controversial.
To determine whether SSD reduces the overall incidence of microbiologically confirmed VAP.
Randomized controlled clinical trial conducted at four French centers. A total of 333 adult patients intubated with a tracheal tube allowing drainage of subglottic secretions and expected to require mechanical ventilation for ≥48 hours was included. Patients were randomly assigned to undergo intermittent SSD (n = 169) or not (n = 164).
Primary outcome was the overall incidence of VAP based on quantitative culture of distal pulmonary samplings performed after each clinical suspicion. Other outcomes included incidence of early- and late-onset VAP, duration of mechanical ventilation, and hospital mortality. Microbiologically confirmed VAP occurred in 67 patients, 25 of 169 (14.8%) in the SSD group and 42 of 164 (25.6%) in the control group (P = 0.02), yielding a relative risk reduction of 42.2% (95% confidential interval, 10.4-63.1%). Using the Day 5 threshold, the beneficial effect of SSD in reducing VAP was observed in both early-onset VAP (2 of 169 [1.2%] patients undergoing SSD vs. 10 of 164 [6.1%] control patients; P = 0.02) and late-onset VAP (23 of 126 [18.6%] patients undergoing SSD vs. 32 of 97 [33.0%] control patients; P = 0.01). VAP was clinically suspected at least once in 51 of 169 (30.2%) patients undergoing SSD and 60 of 164 (36.6%) control patients (P = 0.25). No significant between-group differences were observed in duration of mechanical ventilation and hospital mortality.
Subglottic secretion drainage during mechanical ventilation results in a significant reduction in VAP, including late-onset VAP. Clinical trial registered with www.clinicaltrials.gov (NCT00219661).
呼吸机相关性肺炎(VAP)会导致较高的发病率和死亡率。关于声门下分泌物引流(SSD)预防 VAP 的作用仍存在争议。
确定 SSD 是否能降低微生物学确诊的 VAP 总发生率。
在法国的 4 个中心进行了一项随机对照临床试验。共纳入 333 例因预计需要机械通气≥48 小时而接受气管插管且允许引流声门下分泌物的成年患者。患者被随机分为间歇性 SSD 组(n = 169)或非 SSD 组(n = 164)。
主要结局是根据每次临床怀疑后进行的远端肺部样本定量培养来确定的 VAP 总发生率。其他结局包括早发性和晚发性 VAP 的发生率、机械通气时间和住院死亡率。67 例患者发生了微生物学确诊的 VAP,SSD 组 25 例(14.8%),对照组 42 例(25.6%)(P = 0.02),SSD 组的相对风险降低了 42.2%(95%可信区间,10.4-63.1%)。使用第 5 天的阈值,SSD 减少 VAP 的有益效果在早发性 VAP 中得到了观察(SSD 组 169 例患者中有 2 例[1.2%],对照组 164 例患者中有 10 例[6.1%];P = 0.02)和晚发性 VAP 中(SSD 组 126 例患者中有 23 例[18.6%],对照组 97 例患者中有 32 例[33.0%];P = 0.01)。169 例 SSD 组中有 51 例(30.2%)和 164 例对照组患者(36.6%)至少有一次临床怀疑发生 VAP(P = 0.25)。SSD 组和对照组患者的机械通气时间和住院死亡率无显著差异。
机械通气期间进行声门下分泌物引流可显著降低 VAP 的发生率,包括晚发性 VAP。该临床试验已在 www.clinicaltrials.gov 注册(NCT00219661)。